TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24814717

Group type: EXPERIMENTAL
Intervention: Risky driving (hostile, reckless, and drinking and driving)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Conduct behaviour problems after age 15
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Problem drinking
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Depressive symptoms and conduct behaviour problems before age 15
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Gender (males)
Number of subjects: 312
Study: 24814743

Group type: EXPERIMENTAL
Intervention: Comprehensive, validated questionnaire on functional impairments and QoL administered at diagnosis and after one, two, and five years.
Number of subjects: 1500
Study: 24814759

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 8790

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 8790

Group type: COMPARATOR
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 8790
Study: 24814917

Group type: EXPERIMENTAL
Intervention: Complaint categories established from patient admissions
Number of subjects: 9863
Study: 24815803

Group type: EXPERIMENTAL
Intervention: 3 months follow-up
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: 12 months follow-up
Number of subjects: 821
Study: 24816198

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/d
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/d
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/d
Number of subjects: 3570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (all doses combined)
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (elderly, all doses combined)
Number of subjects: 3570

Group type: COMPARATOR
Intervention: Placebo (elderly)
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (maintenance)
Number of subjects: 3570

Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (open-label stabilization period)
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (randomized period)
Number of subjects: 3570

Group type: COMPARATOR
Intervention: Placebo (randomized period)
Number of subjects: 3570
Study: 24816240

Group type: EXPERIMENTAL
Intervention: Monitoring minimal residual disease (MRD) using quantitative real-time polymerase chain reaction (qPCR) after induction therapy.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: NPM1 mutation ratio cut-off of 0.01 after induction therapy.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of relapse after 2 years for patients with NPM1 ratios above the cut-off.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of relapse after 2 years in the favorable subgroup according to European LeukemiaNet.
Number of subjects: 158
Study: 24816856

Group type: EXPERIMENTAL
Intervention: Eliglustat (50 or 100 mg) self-administered orally twice daily
Number of subjects: 19
Study: 24816908

Group type: EXPERIMENTAL
Intervention: Combination of ganitumab (18 mg/kg) and conatumumab (15 mg/kg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ganitumab alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conatumumab alone
Number of subjects: 78
Study: 24817528

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to both quadriceps for 45 minutes at a stimulation frequency of 50 Hz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 20
Study: 24817603

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg BiD for 5 days every week) + Bevacizumab (5 mg/kg intravenously every 14 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sorafenib + Bevacizumab
Number of subjects: 14
Study: 24819055

Group type: EXPERIMENTAL
Intervention: (166)Ho-microsphere SPECT/CT imaging
Number of subjects: 14

Group type: COMPARATOR
Intervention: (166)Ho-microsphere planar scintigraphy
Number of subjects: 14

Group type: COMPARATOR
Intervention: (99m)Tc-MAA SPECT/CT imaging
Number of subjects: 14

Group type: COMPARATOR
Intervention: (99m)Tc-MAA planar scintigraphy
Number of subjects: 14
Study: 24819148

Group type: EXPERIMENTAL
Intervention: Carriers of C9ORF72 mutation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncarriers
Number of subjects: 0
Study: 24819256

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Obesity risk allele at FTO SNP rs9939609
Number of subjects: 346
Study: 24819395

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10mg and melphalan 2mg for 21 days/28
Number of subjects: 20
Study: 24819685

Group type: EXPERIMENTAL
Intervention: OPB-31121 at 300 mg BID
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OPB-31121 at 350 mg BID
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OPB-31121-related adverse events
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of OPB-31121
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall treatment outcome
Number of subjects: 30
Study: 24819684

Group type: EXPERIMENTAL
Intervention: everolimus + 5-FU/LV
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: everolimus + mFOLFOX6
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: everolimus + mFOLFOX6 + panitumumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: everolimus + 5-FU/LV + mFOLFOX6
Number of subjects: 36
Study: 24820045

Group type: COMPARATOR
Intervention: CRVPP in controls
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CRVPP in early glaucoma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CRVPP in moderate glaucoma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CRVPP in advanced glaucoma
Number of subjects: 34

Group type: COMPARATOR
Intervention: OPP1 in controls
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OPP1 in early glaucoma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OPP1 in moderate glaucoma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OPP1 in advanced glaucoma
Number of subjects: 34

Group type: COMPARATOR
Intervention: OPP2 in controls
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OPP2 in early glaucoma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OPP2 in moderate glaucoma
Number of subjects: 34
Study: 24820437

Group type: EXPERIMENTAL
Intervention: Dietary pulses (beans, peas, chickpeas, lentils)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isocaloric controls
Number of subjects: 9
Study: 24821352

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 737
Study: 24821357

Group type: EXPERIMENTAL
Intervention: Recent IPV victimization
Number of subjects: 203
Study: 24821356

Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoid (SC) products
Number of subjects: 42

Group type: COMPARATOR
Intervention: Current marijuana and tobacco use
Number of subjects: 42
Study: 24821713

Group type: EXPERIMENTAL
Intervention: Interferon β-1b (IFNβ-1b) during pregnancy
Number of subjects: 99
Study: 24821881

Group type: EXPERIMENTAL
Intervention: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC)
Number of subjects: 44
Study: 24821883

Group type: EXPERIMENTAL
Intervention: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) with pegfilgrastim support
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ddMVAC
Number of subjects: 39
Study: 24823514

Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment
Number of subjects: 950
Study: 24823675

Group type: EXPERIMENTAL
Intervention: Anaemia (defined as haemoglobin <12 g/dL for women and <13 g/dL for men)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Non-anaemic patients
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 929
Study: 24824628

Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m² on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8 for up to 8 cycles
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (GP)
Number of subjects: 64
Study: 24824852

Group type: EXPERIMENTAL
Intervention: Weekly dose-intensified cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (80 mg/m²) regimen for eight cycles
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Weekly dose-intensified cisplatin, epirubicin, and paclitaxel regimen
Number of subjects: 29
Study: 24825411

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg once daily (days 1-5 and 12-16)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg/ritonavir 100 mg once daily (days 6-16)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Darunavir/ritonavir
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 28
Study: 24825563

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) of resting oxygen saturation (Spo2) in COPD populations.
Number of subjects: 4368
Study: 24826798

Group type: EXPERIMENTAL
Intervention: sorafenib added to endocrine therapy
Number of subjects: 11
Study: 24827131

Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184)
Number of subjects: 25
Study: 24827135

Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) combined with FEC100 (5-fluorouracil 500 mg/m², epidoxorubicin 100 mg/m², cyclophosphamide 500 mg/m²) followed by docetaxel (100 mg/m²), administered for eight cycles q.3 weeks and four cycles of FEC100 q.3 weeks, followed by four cycles of docetaxel q.3 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panitumumab in combination with FEC100 followed by docetaxel
Number of subjects: 60
Study: 24828895

Group type: EXPERIMENTAL
Intervention: Alleviating manoeuvres (AM) used by 138 patients
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Light touch (sensory trick)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Presence or location of AM
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Clinical predictors of effective AM
Number of subjects: 154
Study: 24829202

Group type: EXPERIMENTAL
Intervention: Oral 6-mercaptopurine (6MP)
Number of subjects: 298
Study: 24829343

Group type: EXPERIMENTAL
Intervention: RV144 HIV-1 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24829444

Group type: EXPERIMENTAL
Intervention: Preoperative anaemia (severe and moderate)
Number of subjects: 39309

Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 39309

Group type: COMPARATOR
Intervention: Normal preoperative Hb concentrations
Number of subjects: 39309
Study: 24829492

Group type: EXPERIMENTAL
Intervention: 5-month fish-oil supplementation providing 1.4 g DHA/d plus 1.8 g EPA/d
Number of subjects: 34
Study: 24829746

Group type: EXPERIMENTAL
Intervention: 10 μg CEA peptide (Arm A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 100 μg CEA peptide (Arm B)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1000 μg CEA peptide (Arm C)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study: 24829756

Group type: EXPERIMENTAL
Intervention: pINGmuTyr vaccine at 1.5 mg dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: pINGmuTyr vaccine at 0.2 mg and 0.5 mg doses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: pINGmuTyr vaccine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: pINGmuTyr vaccine followed by ipilimumab
Number of subjects: 24
Study: 24829759

Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin 21 (IL-21) plus sorafenib (400 mg twice daily)
Number of subjects: 52
Study: 24830339

Group type: EXPERIMENTAL
Intervention: Fixed combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Number of subjects: 0
Study: 24831647

Group type: EXPERIMENTAL
Intervention: MitraClip procedure
Number of subjects: 27
Study: 24831720

Group type: EXPERIMENTAL
Intervention: Eyelash line resection
Number of subjects: 24
Study: 24831981

Group type: EXPERIMENTAL
Intervention: Lenalidomide (15 mg oral on days 1-14) plus R-CHOP21 (375 mg/m² rituximab, 750 mg/m² cyclophosphamide, 50 mg/m² doxorubicin, 1.4 mg/m² vincristine on day 1, and 40 mg/m² prednisone on days 1-5)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus R-CHOP21
Number of subjects: 49
Study: 24834795

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg) subcutaneously every four weeks, with additional doses on study days 8 and 15.
Number of subjects: 271
Study: 24835462

Group type: EXPERIMENTAL
Intervention: Eliglustat
Number of subjects: 19
Study: 24835828

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG IUS)
Number of subjects: 11
Study: 24836083

Group type: EXPERIMENTAL
Intervention: HAM-D6
Number of subjects: 2242

Group type: EXPERIMENTAL
Intervention: IDS-C6
Number of subjects: 2242

Group type: EXPERIMENTAL
Intervention: HAM-D6 and IDS-C6
Number of subjects: 2242

Group type: COMPARATOR
Intervention: HAM-D17
Number of subjects: 2242

Group type: COMPARATOR
Intervention: IDS-C30
Number of subjects: 2242
Study: 24836963

Group type: EXPERIMENTAL
Intervention: Etravirine (ETV) plus two active NRTIs
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Etravirine (ETV) (once or twice daily)
Number of subjects: 287
Study: 24839031

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg subcutaneous monthly for 6 months
Number of subjects: 3280

Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 3280

Group type: COMPARATOR
Intervention: Physician expectations
Number of subjects: 3280
Study: 24840041

Group type: EXPERIMENTAL
Intervention: Permanent iodine-125 seed implantation (PI)
Number of subjects: 6927
Study: 24840763

Group type: EXPERIMENTAL
Intervention: Abdominal and lower-extremity compression during head-upright tilt table testing
Number of subjects: 20
Study: 24842896

Group type: COMPARATOR
Intervention: PCOS women (cohort-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCOS women (cohort-2)
Number of subjects: 100
Study: 24843058

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 1
Study: 24843416

Group type: EXPERIMENTAL
Intervention: BIAsp70 (thrice-daily injections)
Number of subjects: 289
Study: 24843486

Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 24843499

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg/day
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.9 mg/day
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 264
Study: 24843518

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg/day
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 24843520

Group type: EXPERIMENTAL
Intervention: Diet plus low-dose pravastatin (10-20 mg/day, average 8.3 mg during follow-up)
Number of subjects: 7832

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 7832
Study: 24843528

Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg/day
Number of subjects: 400

Group type: COMPARATOR
Intervention: glibenclamide 1.25-2.5 mg/day
Number of subjects: 400
Study: 24843530

Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day
Number of subjects: 123
Study: 24843529

Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 117
Study: 24843582

Group type: EXPERIMENTAL
Intervention: 1500 mg ginsam
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2000 mg ginsam
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3000 mg ginsam
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24843595

Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg (n=268)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: liraglutide 0.6 mg, 0.9 mg (n=176)
Number of subjects: 664

Group type: COMPARATOR
Intervention: glibenclamide 2.5 mg (n=132; trial A)
Number of subjects: 664

Group type: COMPARATOR
Intervention: placebo (n=88; trial B)
Number of subjects: 664
Study: 24843617

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg + glimepiride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg + glimepiride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin + glimepiride (both dosages)
Number of subjects: 0
Study: 24843631

Group type: EXPERIMENTAL
Intervention: Exenatide once-weekly (EQW)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Exenatide twice-daily (EBID)
Number of subjects: 681
Study: 24843632

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 65
Study: 24843649

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 24843650

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 136
Study: 24843697

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy (10, 20, and 40 mg)
Number of subjects: 440
Study: 24843710

Group type: EXPERIMENTAL
Intervention: Insulin regimen change
Number of subjects: 625
Study: 24843712

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 24843714

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 24843715

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 435
Study: 24843716

Group type: EXPERIMENTAL
Intervention: Empagliflozin 1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24843767

Group type: EXPERIMENTAL
Intervention: Isocaloric high-protein diet (HP group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard diet (ST group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison between HP and ST groups
Number of subjects: 18
Study: 24843782

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Metformin 1,000 mg daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Metformin and Pioglitazone (comparison)
Number of subjects: 81
Study: 24844270

Group type: EXPERIMENTAL
Intervention: Psychiatric symptomatology and problem behaviour assessment using standardised instruments.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Needs for care assessment using standardised instruments.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using standardised instruments.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Caregiver burden assessment using standardised instruments.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Health services utilisation assessment using standardised instruments.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Costs for care assessment using standardised instruments.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Quality of mental healthcare assessment through open questions and problem-focused interviews.
Number of subjects: 600
Study: 24844673

Group type: EXPERIMENTAL
Intervention: PDPN-positive/EpCAM-positive CTC ratio >20%
Number of subjects: 53
Study: 24844912

Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 0
Study: 24844950

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 52
Study: 24846037

Group type: EXPERIMENTAL
Intervention: Genotype-directed therapy
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Any oncogenic driver(s) without genotype-directed therapy
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Oncogenic drivers detected
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Matched targeted therapy or trial
Number of subjects: 1007
Study: 24846496

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg oral dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 10
Study: 24847016

Group type: EXPERIMENTAL
Intervention: Nonobstructive CAD
Number of subjects: 117

Group type: COMPARATOR
Intervention: Obstructive CAD
Number of subjects: 117
Study: 24848067

Group type: EXPERIMENTAL
Intervention: [(11)C]5-hydroxy-tryptophan ([(11)C]5-HTP)
Number of subjects: 19
Study: 24848086

Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) during bladder tasks with warm saline (37°C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) during bladder tasks with cold saline (4-8°C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL warm saline starting with an empty bladder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL warm saline starting with a low prefilled bladder volume (100 mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL warm saline starting with a high prefilled bladder volume (persistent desire to void)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated, repetitive filling of 100 mL cold saline starting with an empty bladder
Number of subjects: 0
Study: 24849582

Group type: EXPERIMENTAL
Intervention: Amuvatinib + Paclitaxel/Carboplatin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Amuvatinib + Carboplatin/Etoposide
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Amuvatinib (100-800 mg/day every 21 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Amuvatinib
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 97
Study: 24849710

Group type: EXPERIMENTAL
Intervention: Intensive, outpatient, behavioral weight management program
Number of subjects: 66
Study: 24849854

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0